HealthTree Podcast: Jonathan Kaufman, MD, Emory University Winship Cancer Inst.

Venetoclax (Venclexta) is being studied in myeloma clinical trials and particular benefit has been seen in 11;14 myeloma patients. It is the first time a true precision medicine drug has been identified in myeloma. Which clinical trial combinations are using venetoclax, which are proving to be the most effective and is it getting closer to approval? Learn about the experiences of its use in 11;14 multiple myeloma patients and clinical trial results outside of this specific patient group. The innovation happening in myeloma is astounding and this is the first time that a personalized therapy has been identified to be effective for myeloma patients with a particular genetic feature. 

Jonathan Kaufman, MD of Emory University's Winship Cancer Institute has been involved in early and later trials for venetoclax in multiple myeloma. Dr. Kaufman is Associate Professor, and serves as Associate Vice-Chair, and as Director of the Division of Hematology in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

Board certified in hematology and medical oncology, Dr. Kaufman's practice includes treating multiple myeloma and amyloidosis patients at Emory University Hospital. As a network physician, he started practicing with Emory Healthcare in 2005. He is also an active clinical and translational researcher in the fields of multiple myeloma, amyloidosis, and bone marrow transplant.

Dr. Kaufman is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with American Society of Clinical Oncology and American Society of Hematology.

Thanks to our episode sponsor, Karyopharm Therapeutics